Skip to content

Clinic Trial in Phase 1 Using Amniotic Membrane for the Skin Replacement in Big Wounds

Clinic Trial in Phase 1 Using Amniotic Membrane for the Skin Replacement in Big Wounds

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01948934
Enrollment
6
Registered
2013-09-24
Start date
2012-06-30
Completion date
2017-02-06
Last updated
2017-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound

Keywords

Skin, Injury, Membrane amniotic, Wound

Brief summary

The purpose of this study is to determine the safety of use of a new therapeutic strategy for the treatment of patients with large wounds

Detailed description

Amniotic membrane (AM) is a useful tissue as a biological dressing with numerous advantages it has a very similar structure to the skin and his biological and immunological properties.

Interventions

PROCEDUREAmniotic membrane in big wounds

The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue

Sponsors

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Acute wounds in granulation phase with a minimum surface of 100cm2 * ≥ 18 years * signing informed consent form * guarantee adherence to protocol

Exclusion criteria

* chronic arterial insufficiency * pregnant patients, lactating women or fertile adults that they don't use an effective contraceptive method * involved in other assay * previous disease; kidney, heart, hepatic, systemic or immune * inability to understand informed consent form

Design outcomes

Primary

MeasureTime frame
serious adverse events12 months
inflammatory changes12 months

Secondary

MeasureTime frameDescription
wound evaluation12 monthsinflammatory condition of the wound,surface,
immunological evaluation12 monthsanti Human Leukocyte Antigen 1 (HLA1),Short Tandem Repeat (STRS) detection
histological evaluation12 monthsTransforming growth factor beta 1 or Transforming growth factor beta (TGFB),wound biopsy
microbiological evaluation12 monthsmicrobiological culture

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026